About this page: Complete safety reference for all hyaluronic acid (HA) dermal fillers distributed by MJS Medicals — including EPTQ (JETEMA), and other HA-based dermal fillers added in the future. Each product page links to this page rather than repeating the full safety content. Always refer to the manufacturer’s official Instructions for Use (IFU) for the specific product administered.

Intended Users & Scope of Use

Hyaluronic acid dermal fillers are prescription medical devices. Administration is restricted to licensed healthcare professionals operating within their scope of practice — physicians, dermatologists, plastic surgeons, registered nurses (under supervision per local regulations), and trained aesthetic practitioners with documented HA filler injection training. The practitioner is responsible for patient screening, anatomic planning, aseptic technique, injection placement, vascular complication management, and post-treatment guidance.

HA dermal fillers are not for personal use, self-injection, administration by non-medical personnel, or sale to retail consumers. MJS Medicals supplies licensed clinics and medical wholesalers exclusively.

Contraindications

Do not administer HA dermal fillers to patients with the following:

  • Known hypersensitivity to hyaluronic acid, lidocaine (for products containing lidocaine), or gram-positive bacterial proteins
  • Active local infection or inflammation at or near the planned injection site — cellulitis, dermatitis, herpes outbreak, acne, open wound
  • Pregnancy or breastfeeding — insufficient safety data; clinical use during these periods is not recommended
  • History of severe allergic reactions, anaphylaxis, or multiple severe allergies
  • Bleeding disorders or anticoagulant therapy — warfarin, DOACs (apixaban, rivaroxaban), heparin, high-dose aspirin — relative contraindication due to elevated bruising and hematoma risk; consider timing with prescriber
  • Autoimmune disorders in active flare — lupus, rheumatoid arthritis (relative; case-by-case assessment)
  • Patients under 18 years for cosmetic indications; pediatric therapeutic indications require specialist supervision
  • Recent dental work, illness, or vaccination within 2 weeks — temporary elevated risk of delayed-onset inflammatory nodules
  • Prior permanent filler at the same site — silicone, PMMA, polyacrylamide gels — incompatible with HA layering
  • Unrealistic patient expectations or body dysmorphic features — psychological screening is part of practitioner responsibility

Possible Side Effects

Common reactions (typically resolve within 3–14 days):

  • Injection-site bruising, swelling, redness, and tenderness
  • Pinpoint bleeding or small hematomas
  • Temporary palpable lumps or asymmetry — usually resolve with massage or settle within 2 weeks
  • Mild itching or transient skin discoloration
  • Headache or facial tightness for 24–48 hours

Less common reactions (typically 1–8 weeks post-injection):

  • Persistent nodules or palpable filler masses
  • Tyndall effect — bluish discoloration when filler placed too superficially
  • Delayed-onset inflammatory reactions, especially following illness, dental work, or vaccination
  • Granuloma formation (rare with modern low-MoD HA fillers)
  • Filler migration outside intended placement zone

Rare but serious — seek immediate medical attention:

  • Vascular occlusion — skin blanching, pain disproportionate to procedure, livedo reticularis pattern
  • Vision loss, eye pain, or visual disturbance — possible retinal artery occlusion
  • Skin necrosis with eschar formation
  • Anaphylaxis — urticaria, angioedema, breathing difficulty
  • Severe or worsening infection at the injection site

⚠ Vascular Complication Warning (Class-Wide)

This is the most serious risk associated with all HA dermal fillers, regardless of brand or manufacturing technology. Inadvertent intra-arterial injection or vascular compression can cause skin necrosis, scarring, blindness, or stroke. The risk applies to every HA filler product on the market.

High-risk anatomical zones:

  • Glabella — supratrochlear and supraorbital arteries; risk of skin necrosis and blindness
  • Nasal dorsum and tip — dorsal nasal and angular arteries; highest blindness risk zone
  • Nasolabial fold — facial / angular artery branches
  • Temple — superficial temporal artery
  • Periocular and tear trough — angular and infraorbital arteries
  • Forehead — supratrochlear, supraorbital, and frontal branches

Risk-reduction measures (practitioner responsibility):

  • Detailed knowledge of facial vascular anatomy and danger zones
  • Aspiration prior to injection (recognizing aspiration is not 100% reliable)
  • Slow injection with low pressure and small volumes per pass
  • Consider blunt cannula (25G–27G) for high-risk zones
  • Continuous patient observation — pain, blanching, visual changes
  • Stop immediately at any sign of vascular event; initiate emergency protocol

Emergency response: Any suspected vascular occlusion is a clinical emergency. Initiate hyaluronidase reversal immediately (see next section) and arrange ophthalmologic consultation if vision symptoms present.

💉 Hyaluronidase Reversal Protocol

A defining safety advantage of HA dermal fillers over permanent fillers (PMMA, silicone, polyacrylamide) is that hyaluronidase enzymatically dissolves HA gel — providing a reversal pathway for vascular complications, overcorrection, nodule formation, and Tyndall effect.

Every clinic injecting HA fillers should maintain immediate access to:

  • Hyaluronidase (Hyalase, Hylenex, or regional equivalent) — multiple vials, in-date
  • Saline for reconstitution
  • Aspirin 325 mg for vascular events
  • Warm compresses for vasodilation
  • Nitroglycerin paste 2% (where available and within practitioner scope)
  • Emergency contact list — ophthalmology, hospital emergency, on-call physician

Dosing varies by event severity and filler volume injected. Refer to current consensus protocols (e.g., DeLorenzi 2017 high-dose pulsed hyaluronidase protocol for vascular events). Hyaluronidase is most effective when administered within hours of the event; delayed treatment reduces efficacy.

Storage & Handling

HA filler storage is significantly simpler than botulinum toxin products — no cold chain required.

  • Temperature: 2–25 °C in original packaging
  • Do not freeze — freezing damages cross-linked HA structure
  • Protect from direct sunlight and heat sources
  • Shelf life: typically 18–24 months from manufacturing date (verify each product’s label)
  • Single-use sterile — discard any unused portion after opening; do not retain partial syringes
  • Inspect before use: syringe seal intact, gel clear without discoloration or precipitation

Shipping: MJS Medicals ships HA fillers in insulated packaging. Routine ambient transit temperatures do not affect HA filler integrity — the cross-linked gel is stable at 2–25 °C, unlike lyophilized botulinum toxin which requires refrigeration.

Upon arrival: inspect packaging, verify syringe seal, store at room temperature (or refrigerated if preferred — but not required), and use within product shelf life.

Patient Aftercare Instructions

Practitioners should brief patients on these post-treatment guidelines:

  • 0–24 hours: Apply cold compresses gently for swelling; avoid touching, pressing, or massaging the treated area unless instructed by the practitioner. Sleep elevated on first night.
  • 0–48 hours: Avoid strenuous exercise, saunas, hot tubs, hot showers, alcohol consumption, and direct sun exposure
  • 0–1 week: Avoid dental procedures (cleaning, extractions) and any facial treatments — laser, chemical peels, microneedling, RF, ultrasound
  • 0–2 weeks: Avoid air travel if possible; pressure changes may exacerbate swelling. Avoid flu shots or major vaccinations.
  • Always: Contact the treating practitioner immediately if any skin blanching, severe pain, vision changes, or signs of infection appear

Aftercare advice may vary by treatment area and practitioner protocol. Patients should follow specific guidance from their treating professional.

🚨 When to Seek Emergency Care

Patients should be informed that the following symptoms require immediate medical attention — do not wait for a follow-up appointment:

  • Severe or worsening pain at the injection site, especially out of proportion to the procedure
  • Skin blanching, color changes, or a mottled/reticulated pattern (livedo reticularis)
  • Vision changes — blurred vision, double vision, partial or complete vision loss
  • Eye pain or severe headache
  • Numbness, weakness, or difficulty speaking (possible neurological event)
  • Difficulty breathing, swelling of the face/lips/tongue/throat (anaphylaxis)
  • Spreading redness, fever, or pus at the injection site (infection)
  • Cold, dark, or necrotic-appearing skin

Regulatory Status

The HA dermal fillers distributed by MJS Medicals are primarily Korean-manufactured (Seoul, South Korea) and approved by the Korean Ministry of Food and Drug Safety (MFDS / KFDA). Many products also hold CE certification (EU/EEA) and ANVISA approval (Brazil). FDA approval status varies by product — most Korean dermal fillers are not currently FDA-approved in the United States.

Regulatory status changes over time. Buyers are solely responsible for verifying the legal status of any product in their jurisdiction before purchase or clinical use. Importation of medical devices without proper authorization may be illegal in some jurisdictions and can lead to package detention, customs penalties, or other consequences.

MJS Medicals is a distributor and does not provide regulatory advice or import certification. Each clinic is responsible for ensuring that products it administers are legally authorized in its jurisdiction.

Liability Disclaimer

MJS Medicals is a distributor of medical aesthetic products. We do not manufacture the products we distribute and we do not provide medical advice. All information on this page and on individual product pages is provided for informational purposes only and does not constitute medical, clinical, dosing, or treatment advice.

Licensed practitioners are solely responsible for: patient selection and screening, treatment planning, anatomical knowledge, aseptic technique, injection administration, vascular complication recognition and management, hyaluronidase reversal protocols, post-treatment patient care, emergency response, and all aspects of clinical decision-making. MJS Medicals assumes no responsibility for clinical outcomes, complications, adverse events, misuse, or any consequence arising from the administration of products it distributes.

Always refer to the manufacturer’s official Instructions for Use (IFU) for the specific product being administered. The manufacturer’s IFU is the authoritative source for indications, contraindications, dosing, administration technique, warnings, and adverse reactions specific to that product.

This page is updated periodically. Information reflects general class-wide standards for hyaluronic acid dermal fillers as of the page’s last revision date. Product-specific labels may contain additional warnings or contraindications not reflected here.

By purchasing HA dermal filler products from MJS Medicals, you confirm that you are a licensed medical professional, you have reviewed this safety information, and you accept full responsibility for clinical use.